Summit Therapeutics plc
(‘Summit’ or the ‘Company’)
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
Oxford, UK, and Cambridge, MA, US, 24 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole in patients with C. difficile infection (‘CDI’) at ID Week 2019, taking place 2-6 October 2019 in Washington, DC. These data further strengthen the connection of ridinilazole’s microbiome preservation to its superior clinical outcomes over the standard of care, vancomycin, in a Phase 2 clinical trial as well as provide insight into the beneficial effect of ridinilazole treatment on the physical and mental effects of CDI in the trial. Details of the poster presentations are below.
Date: Thursday, 3 October 2019
Time: 12:15-1:30pm EDT
Title: Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared to Vancomycin (VAN)
Session: 068. Novel Antimicrobials and Approaches Against Resistant Bugs
Authors: S. Paul, R. Vickers and K. Garey
Date: Saturday, 5 October 2019
Time: 12:15-1:30pm EDT
Title: Narrow-spectrum Antibiotic Treatment of Clostridium difficile Infection Improves Preservation of Intestinal Metabolic Profile
Session: 267. Microbiome, Antibiotics and Pathogenesis
Authors: S. Park, K. Yanagi, A. Kane, D. Snydman, R. Vickers, C. Thorpe and K. Lee
Date: Saturday, 5 October 2019
Time: 12:15-1:30pm EDT
Title: Effect of Broad vs. Narrow Spectrum Clostridioides difficile Treatment on Human Stool Bile Acid Composition Over Time
Session: 267. Microbiome, Antibiotics and Pathogenesis
Authors: C. Thorpe, X. Qian, K. Yanagi, A. Kane, N. Alden, D. Snydman and K. Lee
Copies of the presentations will be available at the start of the poster sessions in the Publications section of Summit’s website, www.summitplc.com.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
Contacts
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking | ||
| Bryan Garnier & Co Limited (Joint Broker) | Tel: | +44 (0)20 7332 2500 |
| Phil Walker / Dominic Wilson | ||
| MSL Group (US) | Tel: | +1 781 684 6652 |
| Erin Anthoine | summit@mslgroup.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Sue Stuart / Sukaina Virji | summit@consilium-comms.com | |
| Lindsey Neville |
-END-